Regeneron Pharmaceuticals Inc. (REGN) shares are trading at higher $523.61 and the avg recommendation for the stock is Moderate Buy, while the current analyst price target stands at $675.04.
To add more color to this target, the company’s high over the last year is $664.64 and the low is $328.13. Over the last 52 weeks, REGN is up 45.18% while the S&P 500 is up 14.95%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, REGN reported a profit of $2.02 billion. Regeneron Pharmaceuticals Inc. also saw revenues increase to $2.29 billion. In addition, REGN has free cash flow of $933.9 million as of 09-2020. The company’s EBITDA came in at $1.11 billion which compares well with its peers.
REGN booked profit margins of 38.30%, its Return on Equity (ROE) is 29.80%, and its Return on Assets is 20.70%. All told, it is clear that, REGN needs to be on your watchlist.
Find out when REGN reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. REGN has a short ratio of 2.31 and outstanding shares of 105.50M.
REGN has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.9 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at 27.36. Regeneron Pharmaceuticals Inc. REGN also noted assets of $16.08 billion at the end of the last quarter. Investors should also keep an eye on sector updates as REGN has historically followed its peers on positive news.
All told, Regeneron Pharmaceuticals Inc. REGN has strung together solid data and demonstrated underlying fundamentals. At its current valuation, REGN represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Regeneron Pharmaceuticals Inc. REGN is now commanding a market cap of 55.44B and a float of 101.98M. REGN is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of REGN stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in REGN, either long or short, and we have not been compensated for this article.